贝伐珠单抗联合放疗及动脉栓塞灌注化疗药物治疗局部晚期宫颈癌的临床观察

Clinical observation of bevacizumab combined with radiotherapy and arterial embolization chemotherapy in the treatment of local advanced cervical cancer

目的探讨贝伐珠单抗联合放疗及动脉栓塞灌注化疗药物治疗局部晚期宫颈癌患者的疗效。方法选取我院2015年4月~2020年4月收治的50例晚期宫颈癌患者作为观察对象,按照治疗方式分为对照组(放疗及动脉栓塞灌注化疗药物治疗)和观察组(贝伐珠单抗联合放疗及动脉栓塞灌注化疗药物治疗),随访并比较两组有效率、疾病控制率、血清肿瘤指标表达水平及不良反应发生率的差异。结果对照组的有效率和疾病控制率分别为20%和64%,观察组的有效率和疾病控制率分别为36%和84%,与对照组相比,观察组的有效率和疾病控制率均明显增加(χ^(2)分别为6.349和10.400;P分别为0.012和0.002);与对照组治疗后的血清鳞状上皮细胞癌抗原(4.22±0.67)μg/L、癌胚抗原水平(21.33±2.44)g/L和CA19-9(33.55±3.63)kU/L的水平相比,观察组各指标水平分别为(2.23±0.32)μg/L、(13.77±2.45)μg/L和(24.72±2.56)kU/L,表达水平均明显减少(P均<0.001);此外,与对照组的肝损伤率(32%)和骨髓抑制率(28%)相比,观察组患者的肝损伤率和骨髓抑制率分别为16%和12%,均显著减少(χ^(2)分别为7.018和8.001;P分别为0.008和0.005)。结论贝伐珠单抗联合放疗及动脉栓塞灌注化疗药物的治疗方式具有增加疗效和降低不良反应的作用。

Objective To investigate the efficacy of bevacizumab combined with radiotherapy and arterial embolization in the treatment of locally advanced cervical cancer.Methods A total of 50 patients with advanced cervical cancer admitted to our hospital from April 2015 to April 2020 were selected as the research objects,and were divided into control group(radiotherapy and arterial embolization chemotherapy drug treatment)and observation group(bevacizumab combined with radiotherapy and arterial embolization chemotherapy drug treatment)according to the treatment method.The differences of effective rate,disease control rate,serum tumor index expression level and incidence of adverse reactions between the two groups were compared.Results Compared with the effective rate(20%)and disease control rate(64%)in control group,the effective rate(32%)and disease control rate(84%)of the observation group were significantly increased(χ^(2)=6.349 andχ^(2)=10.400;P=0.012 and P=0.002,respectively).The levels of serum squamous epithelium cell carcinoma antigen(4.22±0.67)μg/L,carcinoembryonic antigen(21.33±2.44)μg/L and CA19-9(33.55±3.63)kU/L after treatment in control group were significantly higher than(P all<0.001)those in observation group(2.23±0.32)μg/L,(13.77±2.45)μg/L and(24.72±2.56)kU/L,respectively.In addition,the rate of liver injury(16%)and bone marrow suppression(12%)was significantly reduced in the observation group compared with the liver injury(32%)and bone marrow suppression(28%)rate in control group(χ^(2)=7.018 andχ^(2)=8.001;P=0.008 and P=0.005,respectively).Conclusion Bevacizumab combined with radiotherapy and arterial embolization can increase curative effect and reduce adverse reactions.